|Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update|
"Audentes has accomplished a number of significant milestones in 2016, culminating in the successful completion of our initial public offering," stated
Mr. Patterson continued, "We plan to file investigational new drug applications for three of our development programs by the first quarter of 2017, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome and AT982 for the treatment of Pompe disease. We expect to report preliminary data from all three programs in the second half of 2017."
Second Quarter 2016 Financial Results
For more information regarding Audentes, please visit www.audentestx.com.
Forward Looking Statements
Selected Financial Information
Selected Balance Sheet Information:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-reports-second-quarter-2016-financial-results-and-provides-corporate-update-300320960.html